We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

65 hedge funds and large institutions have $58.6M invested in Galectin Therapeutics in 2014 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

18% more funds holding

Funds holding: 55 → 65 (+10)

9% more capital invested

Capital invested by funds: $53.9M → $58.6M (+$4.73M)

45% less call options, than puts

Call options by funds: $1.92M | Put options by funds: $3.46M

Holders
65
Holders Change
+10
Holders Change %
+18.18%
% of All Funds
1.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
22
Reduced
12
Closed
13
Calls
$1.92M
Puts
$3.46M
Net Calls
-$1.54M
Net Calls Change
+$3.75M

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$5.63M
2
BFA
BlackRock Fund Advisors
California
+$4.88M
3
BIT
BlackRock Institutional Trust
California
+$2.43M
4
State Street
State Street
Massachusetts
+$2.12M
5
TCIM
TIAA CREF Investment Management
New York
+$824K

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$3.06M
2
BBA
Baker Bros. Advisors
New York
-$2.49M
3
EI
EAM Investors
California
-$2.48M
4
DCM
Driehaus Capital Management
Illinois
-$2.04M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
51
Citadel Advisors
Florida
$37K +$33.6K +2,698 New
First Manhattan
52
First Manhattan
New York
$23K – – –
VFA
53
Virtus Fund Advisers
Connecticut
$21K +$19.1K +1,537 New
IPC
54
Independent Portfolio Consultants
Florida
$18K +$16.5K +1,325 New
OIA
55
Optimum Investment Advisors
Illinois
$9K -$2.61K -210 -25%
LTFS
56
Ladenburg Thalmann Financial Services
Florida
$7K – – –
BlackRock
57
BlackRock
New York
$7K +$6.08K +488 +16,267%
Barclays
58
Barclays
United Kingdom
$5K +$4.06K +326 +472%
RIA
59
Regal Investment Advisors
Michigan
$4K – – –
TWA
60
TCI Wealth Advisors
Arizona
$4K – – –
PSI
61
Pinnacle Summer Investments
Virginia
$3K – – –
Citigroup
62
Citigroup
New York
$2K -$3.47K -279 -65%
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$1K – – –
Ameriprise
64
Ameriprise
Minnesota
$1K +$498 +40 New
GSC
65
Ground Swell Capital
South Carolina
$1K +$1.25K +100 New
MP
66
Mangrove Partners
Connecticut
– -$3.06M -200,000 Closed
EI
67
EAM Investors
California
– -$2.48M -161,935 Closed
DCM
68
Driehaus Capital Management
Illinois
– -$2.04M -133,187 Closed
Millennium Management
69
Millennium Management
New York
– -$1.08M -70,475 Closed
SFM
70
Soros Fund Management
New York
– -$738K -48,200 Closed
RFC
71
Russell Frank Company
Washington
– -$507K -43,558 Closed
HCM
72
Highbridge Capital Management
New York
– -$474K -30,973 Closed
CCI
73
Columbus Circle Investors
– -$261K -17,026 Closed
TAM
74
Tocqueville Asset Management
New York
– -$207K -13,500 Closed
JP Morgan Chase
75
JP Morgan Chase
New York
– -$165K -10,745 Closed
1 2
3
4

GALT Hedge Fund Activity: Q2 2014 in Review

65 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2014, worth a combined $58.6M — up 8.8% from $53.9M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new GALT positions and 13 closed out — a net gain of 10 holders — while 22 added to existing stakes and 12 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $5.63M. The largest seller was Mangrove Partners, exiting entirely with an estimated $3.06M sold.

  • 65 institutional investors held Galectin Therapeutics (GALT) as of Q2 2014, up from 55 in Q1 2014.
  • Funds reported $58.6M of Galectin Therapeutics stock for Q2 2014, up 8.8% quarter-over-quarter.
  • 23 funds opened new Galectin Therapeutics positions in Q2 2014 and 13 closed out, a net change of +10 holders.
  • The largest Galectin Therapeutics buyer in Q2 2014 was Cormorant Asset Management, an estimated $5.63M added.
  • The largest Galectin Therapeutics seller in Q2 2014 was Mangrove Partners, an estimated $3.06M sold.

Based on aggregated 13F filings for Q2 2014.